Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Utilization and outcomes of eribulin in triple-negative metastatic breast cancer (TN MBC): real-world findings (#168)

Jonathan K Kish 1 , Sarah S Mougalian 2 , Ronda Copher 3 , Lindsay McAllister 1 , Zhixiao Wang 3 , Mile Janevski 4 , Mary Broscious 1
  1. Cardinal Health Specialty Solutions, Dublin, OH, USA
  2. Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
  3. Eisai Inc., Woodcliff Lake, NJ, USA
  4. Eisai Australia, Melbourne, VIC, Australia


This analysis examined demographics, clinical characteristics, and real-world (RW) outcomes for patients (pts) prescribed eribulin (ERI) early vs late for the treatment of TN MBC.


Physicians from the Cardinal Health Oncology Research Network completed electronic case-report forms on adult females with TN MBC and pathologically confirmed metastatic disease who received ERI between 01/01/11 and 01/01/14. Providers indicated treatments by line of therapy (LOT) up to ERI treatment. Data included clinical parameters, treatment events, outcomes, dosing, adverse events, supportive-care medications, and hospitalizations. By design, one-half the sample were early ERI users (LOT 1/2) and one-half were late ERI users (LOT 3+). Kaplan-Meier methods were used to calculate median overall survival (OS).


252 pts with TN MBC were identified by 43 providers; 125 (49.6%) were early ERI users and 127 (50.4%) were late ERI users. Overall, 45.4% were stage IV at diagnosis. Mean age at ERI treatment: 57 years, early ERI users; 54 years, late ERI users. Mean length of follow-up: 27 months (mos) from initiation of first-line metastatic treatment, with 76.2% of pts deceased by the end of follow-up. Mean duration of treatment: 5.6 mos (standard deviation=4.3). Early users were more likely (P=0.05) to have a complete/partial response (CR/PR; 71.1% vs 47.7%) and less likely to have progressive disease (PD; 7.1% vs 12.3%). Median OS was 23.0 mos (95% CI: 18.7–22.4) for early ERI users and 14.7 mos (95% CI: 12.6–16.9) for late ERI users.


RW outcomes of ERI therapy demonstrated response rates in >2/3 of early- and ~1/2 of late-treated pts (not verified by external investigator), considerably higher than in the EMBRACE randomized controlled trial (12%). The estimated RW OS of 14.7 mos for late ERI users is consistent and slightly longer than the 13.1 mos observed in the EMBRACE trial.